Attenuation of Dupuytren’s fibrosis via targeting of the  STAT-1 modulated IL-13RA1 response by Akbar, Moeed et al.
Akbar et al., Sci. Adv. 2020; 6 : eaaz8272     10 July 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
1 of 11
D I S E A S E S  A N D  D I S O R D E R S
Attenuation of Dupuytren’s fibrosis via targeting 
of the STAT1 modulated IL-13R1 response
Moeed Akbar1, Emma Garcia-Melchor1, Sabarinadh Chilaka1, Kevin J. Little2, Shatakshi Sood1, 
James H. Reilly1, Foo Y. Liew1,3, Iain B. McInnes1, Neal L. Millar1*
Fibrotic disorders represent common complex disease pathologies that are therapeutically challenging. Inflam-
mation is associated with numerous fibrotic pathogeneses; however, its role in the multifaceted mechanisms of 
fibrosis remains unclear. IL-13 is implicated in aberrant responses involved in fibrotic disease, and we aimed to 
understand its role in the inflammatory processes of a common fibrotic disorder, Dupuytren’s disease. We demon-
strated T-cells produced IFN-g, which induced IL-13 secretion from mast cells and up-regulated IL-13R1 on fibro-
blasts, rendering them more reactive to IL-13. Consequently, diseased myofibroblasts demonstrated enhanced 
fibroproliferative effects upon IL-13 stimulation. We established IFN-g and IL-13 responses involved STAT dependent 
pathways, and STAT targeting (tofacitinib) could inhibit IL-13 production from mast cells, IL-13R1 up-regulation 
in fibroblasts and fibroproliferative effects of IL-13 on diseased myofibroblasts. Accordingly, utilizing Dupuytren’s 
as an accessible human model of fibrosis, we propose targeting STAT pathways may offer previously unidentified 
therapeutic approaches in the management of fibrotic disease.
INTRODUCTION
Fibrosis is a complex process of aberrant tissue healing, leading to 
loss of physiological tissue structure and function with inflammatory 
processes playing a critical role in disease chronicity. Dupuytren's 
disease of the hand is a classic example of pathological inflammato-
ry fibrosis resulting in a debilitating disorder with a prevalence >7% 
in the United States, and thus, is commonly encountered by surgeon, 
physician, and primary care practitioners. Dupuytren’s disease gen-
erally begins with nodule formation in the palm of the hand, pro-
gressing toward formation of a fibrotic cord toward the fingers, and 
eventually results in contraction and the loss of ability to extend the 
digits (1, 2). Presently, the most common treatment for established 
contractures remains surgical intervention, while the use of collagenase 
injections has offered an alternative to surgical excisions; however, 
patients often have notable residual dysfunction due to irreversible 
fixed flexion deformities of the joints despite these treatments. While 
meticulous mechanistic investigation of inflammatory pathways uti-
lizing the “molecule to clinical” intervention paradigm has shown 
remarkable success in other areas of musculoskeletal therapeutics (3), 
there remains no specific disease-modifying treatment for early dis-
ease or prevention of recurrence in Dupuytren’s disease.
Inflammation is implicated in numerous fibrotic disorders, and 
immune cells produce many cytokines, including transforming growth 
factor– (TGF-), that are pivotal (4–7). The presence of lymphocytes 
and macrophages along with a number of cytokines [tumor necrosis 
factor– (TNF-), interferon- (IFN-), interleukin-1 (IL-1), IL-6, 
and IL-33] has previously been documented in Dupuytren’s tissue 
(2, 8–11). The main cell responsible for matrix deposition and contrac-
tion in Dupuytren's disease has been characterized as alpha smooth 
muscle actin (-SMA)–rich myofibroblasts (2, 10, 12, 13). The initiating 
factors associated within normal fascia fibroblasts-to-myofibroblast 
transdifferentiation in Dupuytren’s disease remain unclear; however, a 
number of chemical and mechanical elements have been described as 
playing a role in this phenomenon (14). One such chemical factor that 
has been extensively studied in Dupuytren’s disease is TGF-, and 
studies have consistently demonstrated up-regulation of TGF- in 
Dupuytren’s disease (2, 9, 12). Furthermore, TGF- is a profibrotic cy-
tokine that not only up-regulates -SMA but also promotes fibroblast 
proliferation and extracellular matrix (ECM) production deposi-
tion (12, 15). In a similar vein, IL-13 is a pleiotropic cytokine produced 
by a gene on chromosome 5 at q31 that is elaborated in substantial 
quantities by appropriately stimulated T cells (16) and is also reported 
to induce secretion and activation of latent TGF- (6). IL-13 has been 
implicated in the pathogenesis of hepatic fibrosis, progressive sys-
temic sclerosis, pulmonary fibrosis, and nodular sclerosing Hodgkin's 
disease (5, 17).
Given that targeting inflammatory pathways has proven encour-
aging in other fibrotic disorders (17, 18), we investigated the role for 
IL-13 signaling as a potential therapeutic target in Dupuytren’s dis-
ease. Here, we report immune cell–driven IL-13 production and sig-
naling in Dupuytren’s disease, which enhances the fibroproliferative 
features of the tissue response primarily through increased IL-13R1 
signaling. By chromatin immunoprecipitation (ChIP), we also show 
enriched signal transducer and activator of transcription 1 (STAT1) 
binding at the IL-13R1 site that drive the enhanced fibrotic re-
sponse in Dupuytren’s disease. We demonstrate manipulation of 
IL-13 signaling and response pathways via small-molecule inhibi-
tion {pan c-Jun N-terminal kinases [Janus kinase (JAK)] inhibitor} 
of STAT phosphorylation as a possible therapeutic target to down 
regulate myofibroblast differentiation and activity in Dupuytren’s 
disease.
RESULTS
IL-13 secretion from mast cells in Dupuytren’s disease
Immunohistochemistry of tissue sections from Dupuytren’s tis-
sue and control fascia demonstrated greater number of cells 
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positively stained for IL-13 (up 30% of cells) in diseased tissue 
sections (Fig. 1A); this was in an addition to a greater cellularity in 
Dupuytren’s tissue compared with control fascia, which appeared 
primarily acellular (fig. S1A). IL-13 can be released from a num-
ber of immune cells such as macrophages, mast cells, and T cells 
(4, 19–22). The majority of CD45+ immune cells were macrophages 
with a smaller percentage of mast cells alongside lymphocytes 
(CD3+ T cells and CD19+ B cells) (Fig. 1B). We subsequently sought 
to stimulate cells released from disaggregated Dupuytren’s tissue 
in vitro to identify IL-13+ cells. We found no evidence that macro-
phages (CD64+ macrophages) or T cells were able to secrete IL-13 
(fig. S1, B and C). In addition, T cells from diseased tissue were 
mainly IFN-+–producing T cells following ex vivo stimulation 
(fig. S1D). A proportion (mean, 21.01 ± 6.53%) of CD117+ mast 
cells did express IL-13, suggesting that mast cells are the primary 
source of IL-13 in Dupuytren’s disease (Fig. 1C). We confirmed 
that exposure to IFN- and TGF- in vitro significantly (P < 0.05) 
increased the production of IL-13 from mast cells as previously 
shown (23, 24)(Fig. 1D). Together, these data suggest IL-13 is pre-
dominantly released from mast cells in Dupuytren’s disease follow-
ing cytokine exposure.
IL-13 drives aberrant fibrotic response in  
Dupuytren’s disease
We next investigated the effect of IL-13 on cell proliferation of dis-
eased and normal fibroblasts. IL-13 significantly (P < 0.01) increased 
proliferation of Dupuytren’s myofibroblasts compared with untreated 
control cells (Fig. 2A), demonstrating that diseased myofibroblasts 
proliferate at a greater rate compared with control fibroblasts fol-
lowing IL-13 exposure. Dupuytren’s diseased is characterized by high-
ly proliferating -SMA–expressing myofibroblasts. Concordantly, 
Dupuytren’s myofibroblasts had significantly (P < 0.05) greater -SMA 
mRNA expression compared with control fibroblasts (fig. S2A). How-
ever, no response in -SMA mRNA expression was observed in re-
sponse to IL-13 stimulation in vitro. As one of the main hallmarks of 
Dupuytren’s disease is dysregulated matrix deposition, particularly 
collagen (12, 25), and as IL-13 is known to directly affect matrix pro-
tein production (26), we sought to determine the effect of IL-13 
on matrix gene expression in both control and diseased cells. We 
observed that collagen 1 production was increased in both control 
and diseased cell following IL-13 exposure (Fig. 2B). However, we 
also noted a greater level of increase in collagen 1 production by 
Dupuytren’s myofibroblasts compared with control fibroblasts 
Fig. 1. Mast cells produce IL-13 in Dupuytren’s disease. (A) Dupuytren’s tissue stained for IL-13, isotype immunoglobulin G (IgG) in the top right corner, using rabbit 
polyclonal IL-13 antibody at ×10 and ×40 magnification. Graph illustrates percentage of cells stained positive for IL-13, means ± SEM, n = 10 for control fascia, n = 10 for 
Dupuytren’s tissue; **P < 0.01. (B) Percentage of immune cells phenotyped from disaggregated Dupuytren’s tissue, means ± SEM, n = 6. (C) IL-13 is produced by mast cells 
from disaggregated Dupuytren’s tissue. Graph illustrates percentage of IL-13+ mast cells, means ± SEM, n = 6; *P < 0.01 with null hypothesis 0% of mast cells produce IL-13. 
(D) IL-13 secretion by human buffy coat–derived mast cells following IFN- and/or TGF- treatment; results are means ± SEM, n = 6; *P < 0.05, **P < 0.01, ***P < 0.001, sig-
nificant difference from untreated cells. #P < 0.05.
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following IL-13 treatment, particularly at higher doses of IL-13. 
Furthermore, the mRNA expression of matrix proteins tenascin-C 
and periostin significantly (P < 0.05) increased to a greater degree 
in Dupuytren’s myofibroblasts compared with control fibroblasts 
following exposure to IL-13 (Fig. 2B) in vitro. To further assess 
whether IL-13 had a greater effect on diseased myofibroblasts, we 
measured the expression of IL-13R2, the decoy receptor, which 
is directly responsive to IL-13 (27). We observed that the increase 
in IL-13R2 gene expression was significantly (P < 0.01) greater in 
diseased cells following exposure to IL-13 in vitro.
As IL-13 signaling is primarily via the phosphorylation of STAT6 
(28), utilizing an antibody specific against pSTAT6 (phosphorylated 
STAT6), we confirmed significantly (P < 0.05) greater pSTAT6 in 
diseased cells versus control fibroblasts after IL-13 stimulation 
(Fig. 2C). This confirmed enhanced IL-13 signaling in Dupuytren’s 
myofibroblasts compared with control fibroblasts.
Enhanced IL13R1 signaling in Dupuytren’s fibroblasts
As both IL-13 signaling and its downstream effects were increased 
in diseased myofibroblasts, we next explored the receptor responsi-
ble for enhanced IL-13 signaling. We confirmed that IL-13 signal-
ing in diseased myofibroblasts was primarily through IL-13R1 by 
pretreating myofibroblasts with an IL-13R1–blocking antibody 
before IL-13 exposure. This resulted in a complete amelioration of 
IL-13–induced STAT6 phosphorylation, ECM protein production, 
and cell proliferation (Fig. 3, A to C). This demonstrated IL-13 sig-
naled through IL-13R1, inducing phosphorylation of STAT6. By ne-
gating IL-13 signaling through blocking of the signaling receptor, we 
were able to prevent myofibroblast proliferation and, in particular, 
inhibit the IL-13–stimulated ECM production: collagen I, tenascin-C, 
and periostin. We observed increased (P < 0.01) IL-13R1 transcript 
and protein expression in diseased myofibroblasts versus control 
fibroblasts (Fig. 3D). We found no difference in IL-4 receptor [which 
IL-13 can also signal through and has been implicated in myofibro-
blast transdifferentiation (29)] expression between diseased and con-
trol cells (fig. S2B), suggesting the transdifferentiation of normal 
fibroblast to myofibroblast results in increased IL-13R1 expression 
and subsequent IL-13 signaling.
Enriched STAT1 binding at IL-13R1 sites drives enhanced 
fibrotic response in Dupuytren’s disease
As our data demonstrated TGF- and IFN- induced IL-13 release 
from mast cells, we next examined whether these cytokines could 
also alter IL-13R1 expression in control fibroblasts as had been 
previously demonstrated in other cells (30). While TGF- exposure 
alone did not significantly (P > 0.05) increase IL-13R1 expression, 
IFN- stimulation induced control fibroblasts to up-regulate IL-13R1 
protein on the cell surface (Fig. 4A). Further to this, treatment of 
normal fibroblasts with both IFN- and TGF- significantly (P < 
0.05) increased the surface expression of IL-13R1 and its tran-
script (Fig. 4A).
Having found that IFN- (Fig. 4A) and STAT1 signaling (fig. 
S3A) has a key role in manifesting the enhanced effects of IL-13 via 
up-regulation of IL-13R1 in Dupuytren’s disease, we investigated 
whether differential STAT1 binding at the IL-13R1 gene locus may 
cause this to enhance its activity by performing ChIP enrichment 
analysis. Using the publicly available UCSC (University of California 
Santa Cruz) genome browser database, we identified a number of 
potential binding sites of interest for STAT1 and SPI1 [a key regula-
tor of myofibroblast differentiation in fibrosis (31)] on the IL-13R1 
gene locus (Fig. 4B). These regions include (i) the promoter (marked 
red); (ii) a possible STAT1 binding site upstream from the promoter, 
which may act as an enhancer site (green); and (iii) an intronic re-
gion that based on the enriched histone H3K27ac mark is associated 
to an active gene regulatory element (purple). In addition, an up-
stream region from the same locus that does not overlap with any of 
the binding sites was analyzed as a negative control (blue). ChIP 
analysis with antibodies against STAT1 and SPI1 demonstrated dif-
ferential STAT1 recruitment at the IL-13R1 gene locus between 
Dupuytren’s myofibroblasts and healthy fibroblasts (Fig. 4C). The 
results showed an enrichment of STAT1 binding at the upstream 
enhancer and intronic binding sites in Dupuytren’s myofibroblasts 
(Fig. 4C). Furthermore, SPI1 ChIP analysis did not show binding at 
Fig. 2. IL-13 drives fibrosis in vitro. (A) Effect of recombinant IL-13 on control fi-
broblast and Dupuytren’s myofibroblast proliferation, means ± SEM, n = 6; * indicates 
significant difference from untreated cells, **P < 0.01, ****P < 0.001; # indicates 
significant difference from control fibroblasts, ####P < 0.0001. (B) Effect of IL-13 on 
collagen 1 production and tenascin-C, periostin, and IL-13R2 gene expression; 
mRNA gene expression expressed as fold change following normalization to 
housekeeping gene [glyceraldehyde-3-phosphate dehydrogenase (GAPDH)] and 
then to relevant untreated cells, n = 6, * indicates significant difference from un-
treated cells, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; # indicates significant 
difference from control fibroblasts, ##P < 0.01, ###P < 0.001. (C) Phosphorylation of 
STAT6 following IL-13 exposure in control fibroblasts and Dupuytren’s myofibroblasts. 
Flow cytometric histograms are representative of unstimulated (broken line) and 
IL-13 stimulated (solid line). Graph demonstrates the change in MFI after IL-13 stimu-
lation, means ± SEM, n = 6; *P < 0.05. MFI, median fluorescence intensity.
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the IL-13R1 gene, at the sites examined in either control fibro-
blasts or diseased myofibroblasts. In summary, these data indicate 
enhanced STAT1 binding at the IL-13R1 gene locus, specifically in 
Dupuytren’s myofibroblasts, which may be the cause of enhanced 
receptors’ activity in disease.
STAT inhibition in Dupuytren’s disease: Translational 
targeting
The effect of IFN- and IL-13 stimulation is dependent on STAT 
phosphorylation (28, 32, 33). We identified IFN-–induced IL-13 
production in mast cells and IL-13R1 expression in fibroblasts are 
accompanied by increased STAT1 phosphorylation (fig. S2), while 
IL-13–driven effects in myofibroblasts are accompanied by STAT6 
phosphorylation (Fig. 2B). Tofacitinib is a JAK inhibitor, which in-
hibits both JAK1 and JAK3 that are vital for STAT1 and STAT6 
phosphorylation (34, 35). As these pathways are vital for increased 
IL-13 production and signaling, we explored the use of this inhibitor 
as a potential therapeutic intervention in Dupuytren’s disease. First, 
we assessed whether tofacitinib could negate the IFN-–induced IL-13 
production by mast cells. We observed that STAT1 phosphoryla-
tion was significantly (P < 0.001) inhibited in cytokine-stimulated 
mast cells that had been pretreated with tofacitinib compared with 
control vehicle alone (Fig. 5A). In addition, the data demonstrated 
that IL-13 produced by cytokine-stimulated mast cells was signifi-
cantly (P < 0.001) lower following tofacitinib pretreatment (Fig. 5A).
We further assessed whether tofacitinib treatment could reduce 
the observed increase in IL-13R1 expression. Initially, we estab-
lished that control fibroblasts treated with tofacitinib before IFN- 
(+TGF-) stimulation did not increase pSTAT1 levels, whereas cells 
pretreated with vehicle alone did (Fig. 5B). Furthermore, IL-13R1 
transcript and protein levels following IFN- plus TGF- exposure 
were significantly (P < 0.01) lower in cells pretreated with tofacitinib 
compared with those pretreated with vehicle control. Together, these 
results demonstrate that STAT1 targeting via tofacitinib is capable 
of inhibiting IFN-–driven IL-13R1 up-regulation observed in dis-
eased myofibroblasts. Last, we ascertained whether tofacitinib could 
inhibit IL-13 signaling in diseased cells. We observed that tofacitinib 
did indeed inhibit IL-13–driven STAT6 phosphorylation (Fig. 5C) 
while additionally abolishing the IL-13–driven changes in periostin, 
tenascin-C, and IL-13R2. Last, we established myofibroblasts 
Fig. 3. Enhanced IL-13 signaling through IL-13R1 in Dupuytren’s myofibroblasts in vitro. Dupuytren’s myofibroblasts were pretreated with anti–IL13R1 before 
exposure to IL-13 (100 ng/ml). (A) Phosphorylation of STAT6. (B) Proliferation of Dupuytren’s myofibroblasts. (C) Effect on collagen 1 production and tenascin-C, periostin, 
and IL-13R2 gene expression. mRNA gene expression expressed as fold change following normalization to housekeeping gene (GAPDH) and then to relevant untreated 
cells. All results are means ± SEM, n = 6; * indicates significant difference from untreated cells, *P < 0.05, **P < 0.01, ***P < 0.001. #P < 0.05, ##P < 0.01, ###P < 0.001. (D) IL-13R1 
protein and transcript expression in control fibroblasts and Dupuytren’s myofibroblasts. Representative flow cytometry histogram of control fibroblasts (blue line) and 
Dupuytren’s myofibroblasts (red line). Graphs illustrates MFI or 2−CT (relative to GAPDH) of IL-13R1, means ± SEM, n = 6; **P < 0.01.
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pretreated with tofacitinib had significantly (P < 0.01) lower levels 
of proliferation following IL-13 exposure than vehicle-pretreated 
cells. Together, these data suggest STAT inhibition may be a viable 
intervention of the different fibroproliferative features observed in 
Dupuytren’s disease.
DISCUSSION
This study demonstrates that the local tissue environment in Dupuytren’s 
disease is characterized by a milieu of inflammatory cells and cyto-
kines, which not only drive early myofibroblast transdifferentiation 
but also provides the environment for the fibroproliferative chronicity 
of this debilitating disease. We find a milieu of cytokines drive pheno-
typic changes on the stromal cells, and these phenomena are depen-
dent on STAT phosphorylation (Fig. 6), which we are able to inhibit 
in vitro. Together, our results suggest that Dupuytren’s disease has 
a vital immune and inflammatory component driving the fibropro-
liferative chronicity that may be effectively treated by targeting the 
STAT pathway.
IL-13 is synonymous with fibrotic disorders (19, 36, 37), and 
we established the increased presence of mast cell–derived IL-13 in 
Dupuytren’s tissue. One of the principal mechanisms through which 
IL-13 promotes fibrosis is via proliferation of resident stromal cells. 
This hyperproliferation, previously attributed in Dupuytren’s dis-
ease to TGF- responses, encourages cells to lay down increased 
matrix proteins promoting clinical cord and nodule formation. Our 
data suggest the presence of another core mediator of fibrosis, IL-13, 
can also induce significant proliferation of myofibroblasts as well as 
ECM production in Dupuytren’s fibrosis. T cells are also a known 
source of IL-13 and are found in abundance in Dupuytren’s tissue. 
Fig. 4. STAT1 mediated dysregulation of IL13R1 in Dupuytren’s disease. (A) Control fibroblasts exposed to IFN- and/or TGF-. IL-13R1 transcript following treat-
ment. Representative flow cytometry histogram of IL-13R1 expression on the surface of untreated, and graph illustrates MFI of IL-13R1 after treatment. All results are 
means ± SEM; mRNA gene expression expressed as fold change following normalization to housekeeping gene (GAPDH) and then to relevant untreated cells, n = 6; * in-
dicates significant difference from untreated cells, *P < 0.05. #P < 0.05. (B) Identification of sites of interest on IL-13R1 gene locus: nonspecific (blue), enhancer (green), 
promoter (red), and intronic site (purple). (C) Quantitative polymerase chain reaction of ChIP representing percent enriched binding of SPI1 and STAT1 at different sites 
of interest of interest on the IL-13R1 gene. Graph demonstrates the percent enriched following subtraction of nonspecific enrichment, means ± SEM, n = 4; *P < 0.05.
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However, we identified the majority of T cells in Dupuytren’s tissue 
were IFN-–producing cells. While IFN- is not synonymous with 
fibrosis (38, 39) unlike other cytokines (i.e., IL-4, IL-13, TGF-), 
it has also been implicated in fibrotic pathways and pathogenesis 
(23, 24, 40–42). Similar to previous publications (23, 24), we found 
that IFN- (in combination with TGF-) was able to induce human 
mast cells to produce IL-13. We believe that IFN- from T cells can 
induce mast cells to release IL-13 with subsequent fibroproliferative 
changes observed in disease. The data highlight a milieu of cyto-
kines act cooperatively to induce the multicellular fibrotic patho-
genesis observed in Dupuytren’s disease. Rather than being a linear 
hierarchical pathway, it is likely a dynamic fluid environment leads 
to the multifaceted features of fibrotic disorders (Fig. 6). Recent find-
ings also support the role of cytokine and cell cross-talk in driving 
Fig. 5. Inhibition of STAT phosphorylation reduces IL-13 secretion and signaling. (A) STAT1 phosphorylation and IL-13 secretion from human mast cells following 
IFN- and TGF- exposure. Cells were pretreated with tofacitinib or vehicle control [0.001% dimethyl sulfoxide (DMSO)] for 30 min. (B) STAT1 phosphorylation and 
IL-13R1 transcript and protein expression following IFN- and TGF- treatment. Control fibroblasts were pretreated with tofacitinib or vehicle control (0.001% DMSO) for 
30 min before cytokine stimulation. (C) Dupuytren’s myofibroblasts were pretreated with tofacitinib or vehicle control (0.001% DMSO) and then exposed to IL-13 (100 ng/ml). 
STAT6 phosphorylation, myofibroblast proliferation, and periostin, tenascin-C, and IL-13R2 transcript levels. All results are means ± SEM; mRNA gene expression ex-
pressed as fold change following normalization to housekeeping gene (GAPDH) and then to relevant untreated cells, n > 4; * indicates significant difference from untreated 
cells, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001.
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fibrotic disease (11). Both macrophages and, in particular, mast cell 
are synonymous with fibrotic disease, which is further elegantly high-
lighted by the study. Although the study primarily focused on the 
combined effects of TNF- and IL-33, we believe it supports our 
findings. Izadi and colleagues did not record much spontaneous 
IL-13 release (11), which may be due to cells being latent following 
disaggregation from tissue; IL-33 is known to drive IL-13 release from 
mast cells in disease (43). The current study has demonstrated that 
IL-13 release and its downstream fibrotic effects are viable targets 
for therapy. As such, the findings from both studies reinforce that 
fibrotic disease is a result of a complex milieu of cells and cytokines 
working cooperatively in the pathogenesis of fibrosis.
Our data further support the notion that -SMA–high–expressing 
myofibroblast phenotype is primarily due to TGF- (fig. S3C) but 
reveal Dupuytren’s myofibroblasts portray another, to our knowl-
edge, undocumented facet: higher IL-13R1 expression. In addi-
tion, we were able to induce this characteristic in control fibroblasts 
following IFN- exposure in combination with TGF-, a phenomenon 
previously demonstrated in eosinophils (30). As in most cases with 
IFN- (32), the induced IL-13R1 change was dependent on the phos-
phorylation of STAT1. We importantly found increased STAT1 
binding on the IL-13R1 gene at the enhancer and intronic sites, 
thereby facilitating the downstream IL-13 responsiveness. This unique 
binding motif of STAT1 appears to be a hallmark of Dupuytren’s 
myofibroblasts and could represent an interesting therapeutic in-
tervention in the future via epigenetic targeting.
The STAT pathway has been a therapeutic approach in other dis-
ease pathologies through the use of JAK inhibitors (44, 45), a group 
of receptor-associated kinases that are essential for downstream sig-
naling cascade of a number of cytokine receptors. Upon cytokine and 
receptor engagement, JAKs initiate the STAT phosphorylation, lead-
ing to STAT dimerization and, ultimately, target gene induction (44). 
We elected to use tofacitinib as a pan JAK inhibitor, as it has previ-
ously been shown to be effective against IFN- (46) and IL-13 (35) 
signaling in vitro, and safety and efficacy have been demonstrated in 
numerous clinical trials (44) including the treatment of rheumatoid 
arthritis. We successfully inhibited STAT1 phosphorylation, follow-
ing IFN- stimulation, in mast cells and control fibroblasts, resulting 
in no downstream increase in IL-13 secretion and IL13R1 expression, 
respectively. Furthermore, tofacitinib treatment inhibited IL-13- 
induced STAT6 phosphorylation in diseased myofibroblasts, leading 
to reduced cell proliferation and matricellular protein up-regulation. 
Together, we demonstrate that targeting of the JAK/STAT pathway 
can inhibit cytokine production, fibroblast-to-myofibroblast trans-
differentiation, and fibroproliferation of myofibroblasts, advocating 
it as a translational target in Dupuytren’s disease.
While we demonstrate effective targeting of IL-13 production 
and signaling, we acknowledge a critical role of TGF- in driving 
Dupuytren’s disease. Many of the effects we observed occur in the pres-
ence of TGF-, while myofibroblast transdifferentiation via -SMA 
expression is principally TGF- dependent (47). However, direct and 
universal inhibition of TGF- may not be suitable given its function 
in a broad range of physiological pathways and various isoforms 
(7, 48), while in vivo studies have documented increased inflamma-
tion, tumor production, and toxicity (49–51). In addition, clinical 
trials have demonstrated limited long-term efficacy in fibrotic dis-
orders to date (47). Furthermore, -SMA expression may only be 
an indicator of fibrotic conditions and not causative (52); thus, di-
rect targeting of it may be futile.
We acknowledge that our experimental datasets lack in vivo an-
imal data. Although a number of animal models have been used to 
study cytokine-driven fibrotic pathogenesis, there is no well-described 
in vivo model available for Dupuytren’s disease. There have been at-
tempts to describe rodent models; however, these xenograft models 
rely on implanting human cells into mice or rats (53, 54). In addi-
tion, the outcomes of using these model studies do not document 
Fig. 6. Targeting STAT phosphorylation in Dupuytren’s disease. Schematic diagram illustrating the cytokine-driven milieu in which Dupuytren’s disease may manifest. 
The presence of IFN-–secreting T cells results in IL-13 production from mast cells in addition to fibroblast undergoing myofibroblast transdifferentiation in the presence 
of TGF-. These inflammatory interactions drive fibroproliferative remodeling, which can be inhibited by use of STAT inhibitors such as tofacitinib.
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any clinical-like outcomes but rather those already investigated in vitro 
(i.e., TGF- levels and -SMA and collagen expression) (55–57). In 
addition, while we were able to measure collagen protein levels fol-
lowing IL-13 stimulation, we measure mRNA expression for other 
matrix proteins (tenascin-C and periostin). However, this was pri-
marily to highlight that changes in these genes were due directly to 
IL-13, and any subsequent intervention in the IL-13 pathway would 
impede changes in these genes. Last, while not statistically signifi-
cant, we also note that our control fascia samples were on average 
7 years younger than that of the Dupuytren’s samples, and thus, 
some aspects may be due to aging effects.
In summary, the current study establishes inflammation-driven 
epigenetic changes in fibroblasts and IL-13 production in the patho-
genesis of Dupuytren’s disease. Dissection of the molecular path-
ways involved reveals pharmacological manipulation of the STAT 
pathways as therapeutic targets to down-regulate myofibroblast dif-
ferentiation and activity. On the basis of our findings, we suggest that 
repurposing of these readily available pharmaceutical agents may 
provide novel proof-of-concept studies in Dupuytren’s disease.
MATERIALS AND METHODS
Study design
The aim of this study was to dissect the role of inflammation, partic-
ularly cytokines, in the manifestation of a common fibrotic pathology: 
Dupuytren’s disease. Furthermore, we aimed to identify whether any 
of the pathways involved could be suitable candidates for therapeutic 
intervention. We identified the presence of immune cells in Dupuytren’s 
disease and their ability to secrete a number of cytokines synonymous 
with fibrosis and inflammation, IL-13 and IFN-. Next, we investi-
gated the fibroproliferative effects of IL-13 in vitro and whether 
there were any differences in control and diseased cells. We then 
sought to investigate the mechanism by which diseased cells were 
more responsive to IL-13 stimulation. Last, we wished to identify 
whether the pathways identified could be inhibited using a currently 
available pharmacological agent that could inhibit the multiple path-
ways involved in disease.
Study approval
Human study procedures and protocols were approved by the Na-
tional Health Service West of Scotland Ethics Committee (REC 11/
S0704/7). Full informed consent was obtained from all patients. 
Sample size for tissue- and cell-based assays was determined on the 
basis of sample availability and technical needs.
Clinical samples
Dupuytren’s samples were collected from patients undergoing sur-
gical fasciectomy for Dupuytren’s contracture (n = 10, 5 females, 
5 males; mean age ± SEM, 50.3 ± 10.2). Control tissue was obtained 
from patients undergoing hand surgery for carpal tunnel syndrome 
unaffected by Dupuytren's disease, characterized as normal palmar 
fascia tissue (n = 10, 5 females, 5 males; mean age ± SEM, 43.3 ± 8.6) 
macroscopically at the time of surgery and microscopically by hema-
toxylin and eosin (H&E) staining before any control experiments.
Histology
Tissue was fixed in 4% paraformaldehyde and embedded in paraffin 
using standard techniques. Sections (5 m) were obtained and stained 
with H&E (Vector Laboratories).
Immunohistochemistry
Histological sections were deparaffinized in xylene and rehydrated 
through graded ethanol. Endogenous peroxidase activity was quenched 
using 3% H2O2. Antigen retrieval was performed using Uni-Trieve. 
Blocking of nonspecific binding was performed using 2.5% horse 
blocking serum (both Vector Laboratories). Sections were incubated 
overnight at 4°C with the primary antibody against IL-13, clone A130D 
(LSBio), or isotype control. Staining of antigens was performed using 
the ImmPRESS and ImmPACT DAB chromagen solution as per the 
manufacturer’s instructions (Vector Laboratories). Sections were coun-
terstained using hematoxylin.
Tissue analysis occurred in two stages by two independent asses-
sors (N.L.M. and J.H.R.) as previously described (58); the first stage 
had all samples being given a semiquantitative grade based on the 
percentage of positively stained cells (taken over the total number of 
cells in that field) in 10 random high-powered fields. The following 
semiquantitative grading was used: grade 0, no staining; grade 1, 
mild, ≤10% of cells stained positive; grade 2, moderate, 10 to 20% of 
cells stained positive; and grade 3, strong, ≥20% of cells stained pos-
itive. The mean of these values was analyzed by an unpaired Student’s 
t test. In the second stage, the samples had 10 random high-powered 
fields analyzed at ×40 magnification, and cells in each field were 
counted manually. The mean percentage of positively stained cells 
was taken over the total number of cells per high-powered field; 
similarly, the results were analyzed by an unpaired Student’s t test.
Ex vivo stimulation
Tissue was digested in Liberase TM (Sigma-Aldrich) in Roswell Park 
Memorial Institute (RPMI) media for 2 hours at 37°C. The digested 
tissue was passed through a 100-m cell strainer, pelleted by centrif-
ugation at 350g for 5 min; the supernatant was discarded. This was 
repeated twice. Cells were either harvested for flow cytometry or un-
derwent the appropriate stimulation for 24 hours listed below before 
harvesting for intracellular flow cytometry. For mast cell stimulation, 
the cell suspension was incubated with human myeloma immuno-
globulin E (IgE) (2 g/ml) (Merck) for 24 hours and followed by in-
cubation with human anti-IgE (5 g/ml) (BioLegend). T cell and 
macrophage stimulation was assessed by stimulating the disaggregated 
cell suspension for 24 hours with phorbol 12-myristate 13-acetate 
(50 ng/ml) plus ionomycin (1 g/ml) and lipopolysaccharide (100 ng/ml) 
(all Sigma-Aldrich), respectively.
Mast cell culture
Human buffy coat–derived mast cells were culture as per previously 
described (53).
Mast cell stimulation
Buffy coat–derived mast cells were incubated with human myeloma 
IgE (2 g/ml) for 24 hours. These cells were then stimulated with 
TGF- (2 ng/ml) and IFN- (10 ng/ml) in the presence of human 
anti-IgE (5 g/ml) (all BioLegend) for 15 min for phosphorylation 
studies or 24 hours for all other studies.
Fibroblast and myofibroblast isolation and culture
Control fibroblasts and Dupuytren’s myofibroblasts were extracted 
from control carpal fascia and Dupuytren’s nodules, respectively. 
Tissue was disaggregated as described above, and cell suspension 
was resuspended in supplemented culture medium [RPMI with 10% 
fetal bovine serum, 1% penicillin/streptomycin, and 1% l-glutamine 
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(all Invitrogen)] at 37°C, 5% CO2, and 95% humidity. Cultures were 
maintained at 37°C in a humidified atmosphere of 5% CO2. Cells 
were subcultured and trypsinized at subconfluency and used at pas-
sages 2 to 4.
In vitro fibroblast and myofibroblast stimulation
Cells were plated in 12-well culture plates at a density of 5 × 104 cells 
per well with 1 ml of supplemented culture medium and allowed to 
adhere 48 hours before stimulation. Cells were stimulated with the 
appropriate recombinant human cytokine diluted in supplemented 
culture medium for 24 hours unless stated below. The concentra-
tions of cytokines used were as follows: IL-13, 1 to 100 ng/ml; TGF-, 
2 ng/ml; and IFN-, 10 ng/ml (all BioLegend). After the stimulation 
period, supernatants were collected, and cells were harvested for the 
appropriate assay.
For the cell proliferation assay, cells were serum starved overnight 
before stimulation. The stimulation period was 72 hours. Cells for 
the phosphorylation studies were also serum starved overnight be-
fore stimulation for 15 min.
Flow cytometry
Single-cell suspensions were labeled with fluorophore-conjugated 
anti-mouse antibodies (Table 1) and Zombie viability dye at recom-
mended dilutions following the manufacturers’ recommendations 
(BioLegend). Where adherent cells were used, cells were first rinsed 
with phosphate-buffered saline (PBS) and then detached using Ac-
cutase (BioLegend) as per the manufacturer’s instructions. For phos-
phorylation studies, BD Phosflow (BD Biosciences) antibodies and 
protocols were used as described by the manufacturer. Data were 
acquired on BD LSR II using FACS (fluorescence-activated cell sort-
ing) DIVA software with automated compensation (BD Biosciences). 
Compensation data were acquired using single stained BD Comp 
beads as per the manufacturer’s instructions (BD Biosciences). All 
data were analyzed using FlowJo software (Tree Star). 
Gene expression
Cells were harvested in PureLink lysis buffer containing 1% 2- 
mercaptoethanol, and RNA was extracted using mini columns ac-
cording to the PureLink protocol (Thermo Fisher Scientific). RNA 
concentration and purity were determined using a spectrophotometer 
(Nanodrop 2000, Thermo Fisher Scientific). RNA (100 ng) was con-
verted to cDNA using High-Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher Scientific) according to the manufacturer’s in-
structions. cDNA was diluted 1 in 5 using ribonuclease-free water. 
Quantitative polymerase chain reaction (qPCR) was performed 
using PowerUp SYBR Green Master Mix (Thermo Fisher Scientific). 
Each sample was run in duplicate and normalized to endogenous 
control [glyceraldehyde-3-phosphate dehydrogenase (GAPDH)] fol-
lowing confirmation that there was no more than 0.25 cycle 
difference in the control gene between each treated condition. Data 
represent relative mRNA expression (2−CT) or fold change from 
untreated cells (2−CT).
Primers (Integrated DNA Technologies) were as follows: GAPDH, 
(f) 5′-TCGACAGTCAGCCGCATCTTCTTT-3′ and (r) 5′-ACCA-
AATCCGTTGACTCCGA CCTT-3′;
Tenascin-C, (f) 5′-CTTTGGCTGGGTTGCTTGAC-3′ and (r) 
5′-GTGCCAGGAGACCGTACCAC-3′; Periostin, (f) 5′-TTG AGA 
CGC TGG AAG GAA AT-3′ and (r) 5′-AGA TCC GTG AAG GTG 
GTT TG-3′; IL-13R1, (f) 5′-CTTCCCGTGTGAAACCTGAT-3′ 
and (r) 5′-GTGTCTCAGTTTGGCTGTTATTG-3′; IL-13R2, (f) 
5′-AGCATACCTTTGGGACCTAT-TC-3′ and (r) 5′-TCAACTG-
TAGCAGTCACCAAG-3′; -SMA, (f) 5′-CCT CCC TTG AGA 
AGA GTT ACG A-3′ and (r) 5′-GAC TCC ATC CCG ATG AAG 
GAT-3′.
Proliferation assay
Cell proliferation was assessed using the Cell Proliferation Kit I 
(MTT) as per the manufacturer’s protocol (Sigma-Aldrich).
Chromatin immunoprecipitation
Cultured cells were washed with PBS and cross-linked with 1% form-
aldehyde, followed by cell lysis using SDS buffer. Lysate was soni-
cated with Bioruptor UCD-200 (Diagenode), followed by incubation 
with Dynabeads (Invitrogen) conjugated with rabbit-derived anti-
bodies: SPI1, STAT1, or isotype control (all Cell Signaling Technology). 
Protein/DNA/bead complexes were washed with radioimmuno-
precipitation assay buffer (RIPA buffer), RIPA + NaCl, LiCl, and 
TE buffer. Protein/DNA complexes were eluted with elution buf-
fer. Reverse cross-linking was performed overnight at 65°C, fol-
lowed by DNA purification and qPCR. ChIP signal was normalized 
to total chromatin input (percent input), which was calculated as 
100 × 2(CTinput-CTtarget).
Primers (Integrated DNA Technologies) were as follows: Promoter, 
(f) 5′-FW CAG GAA ACG CCT AAG GAC TC-3′ and (r) 5′-AAG-
GGATGGGAGGTGAATCG-3′; Enhancer, (f) 5′-ATCTCTCTCA-
CCTTTGGCGC-3′ and (r) 5′-ATGCAGTGAGTAGAGGCTGG-3′; 
Intronic, (f) 5′-TCTTGTCTCACGGCACCTTG-3′ and (r) 5′-AAA-
CAAGACACAGCTCCCGC-3′; Negative Control, (f) 5′-GGCTA-
CCCAGAGTAATGACC-3′ and (r) 5′-GAAGAAAGGGACATG-
GCAGC-3′.
Collagen I assay
Collagen I from culture supernatant was determined using either 
single-antibody enzyme-linked immunosorbent assay kits (R&D Sys-
tems) as per the manufacturer’s instructions.
Statistical analysis
All data are shown as means ± SEM. All statistical analyses, in-
cluding Shapiro-Wilk normality test, analysis of variance (ANOVA), 
Fisher’s least significant difference with Bonferonni correction for 
multiple comparisons, and Student’s t test, were performed using 
GraphPad Prism 7 software. A P value of <0.05 was considered 
significant.








Zombie viability dye All viable cells
 o
n







Akbar et al., Sci. Adv. 2020; 6 : eaaz8272     10 July 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
10 of 11
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/28/eaaz8272/DC1
View/request a protocol for this paper from Bio-protocol.
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